Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.

Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale - MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity ...

Hearing loss may raise Parkinson’s risk by 57% per 10-decibel drop. Study calls for integrated care strategies.

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

At Rock Steady Boxing West Michigan, patients are using boxing as a form of therapy to combat the effects of Parkinson's.

Parkinson's disease affects not only muscle movement but also the mental health of those diagnosed. While there is no cure, staying active is key to managing the disease.

Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...

So I really depend on my medication." Sir Peter Luff, a former defence minister and MP for Mid Worcestershire, explained how ...

WEST BEND, Wis. — Rock Steady Boxing participants live with a form of Parkinson's disease and want to raise awareness and ...

Patients living with Parkinson’s disease are encouraged to engage in regular exercise to help manage symptoms and improve ...

People who have Parkinson’s disease aren’t alone. That was something it took Ted Stephens of St. James a while to learn after ...

A delay in getting to the rapid eye movement (REM) stage of sleep may be linked to Alzheimer's disease and related dementias, ...